Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement - 14/03/26
Doi : 10.1016/j.tjpad.2026.100533
Limoran Tang a, b, Yun Xu a, b, c, d, ⁎ 
, Hui Zhao a, b, c, d, ⁎
, Hui Zhao a, b, c, d, ⁎ a Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
b Department of Neurology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University, Nanjing 210008, China
c Department of Neurology, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing 210008, China
d Department of Radiology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China
⁎ Corresponding authors at: Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 ZhongShan Road, Nanjing, Jiangsu, 210008, China. Department of Neurology Affiliated Drum Tower Hospital of Nanjing University Medical School 321 ZhongShan Road Nanjing Jiangsu 210008 China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
Plan
© 2026
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 13 - N° 5
Article 100533- mai 2026 Retour au numéro
Article précédent
- Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial
- Jasmin A. Duehring, Diane M. Jacobs, David P. Salmon, Andrew J. MacKelfresh, Carolyn Revta, Antje Meyer, Michael Schaeffer, Sylvia Schell-Mader, Tanja Wassmann, Christine Wenzkowski, Howard H. Feldman, Steven D. Edland, ADCS VIVA-MIND Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.